Anti-EBV Latent Membrane Protein 1 [LMPO24]

Monoclonal antibody which can be used to investigate EBV latency and EBV-associated malignant cells.

Contributors

Inventor Institute
Martin Rowe University of Birmingham
Cat. #: 152632
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Microbiology
Application: FACS ; IHC
Target: Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)
Reactivity: Virus
Clone: LMPO24
Host: Mouse
Class: Monoclonal
Product description: Monoclonal antibody which can be used to investigate EBV latency and EBV-associated malignant cells. Background and Research Application EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. This antibody is specific for latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV). LMP1 is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. This protein can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Immunogen: Purified plasma membranes from LMP1 expressing insect cells infected with a recombinant LMP1 baculovirus
Immunogen Uniprot ID: P03230
Target background: Monoclonal antibody which can be used to investigate EBV latency and EBV-associated malignant cells. Background and Research Application EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. This antibody is specific for latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV). LMP1 is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. This protein can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Niedobitek et al. 1995. Blood. 86(2):659-65. PMID: 7605996.

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Related Tools for Antibodies

Cat. # Tool Name
151016 Anti-CyclinA [E72.1] Key Info View Tool
151035 Anti-CD8 [14] mAb Key Info View Tool
151037 Anti-Cdk1 [17 (A17)] Key Info View Tool
151039 Anti-Integrin aVb3 [23C6] Key Info View Tool
151018 Anti-Mos [R38.1] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.